Clinical Trial Results:
A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients with Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
Summary
|
|
EudraCT number |
2018-003671-35 |
Trial protocol |
EE LV BG HU PL RO |
Global end of trial date |
27 May 2020
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
29 May 2022
|
First version publication date |
29 May 2022
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
SPR994-301
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT03788967 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Spero Therapeutics, Inc.
|
||
Sponsor organisation address |
Baarerstrasse 113, Zug, Switzerland, United States, 6300
|
||
Public contact |
Angela Talley, Senior Vice President Clinical Development, +1 857-242-1575, atalley@sperotherapeutics.com
|
||
Scientific contact |
Angela Talley, Senior Vice President Clinical Development, +1 857-242-1575, atalley@sperotherapeutics.com
|
||
Sponsor organisation name |
Spero Therapeutics, Inc.
|
||
Sponsor organisation address |
Baarerstrasse 113, Zug, Switzerland, United States, 6300
|
||
Public contact |
Hanna Kwak, Spero Therapeutics, Inc., +1 857-242-1568, Hkwak@sperotherapeutics.com
|
||
Scientific contact |
Hanna Kwak
, Spero Therapeutics, Inc., +1 857-242-1568, Hkwak@sperotherapeutics.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
27 May 2020
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
27 May 2020
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The main objective of the trial is to assess the overall response (combined clinical cure plus microbiological eradication) of oral Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) compared to intravenous (IV) ertapenem in subjects ≥18 years of age with cUTI/AP and to assess the safety of oral TBPM-PI-HBr compared to IV ertapenem in subjects ≥18 years of age with cUTI/AP.
|
||
Protection of trial subjects |
All subjects signed the informed consent form provided by investigator.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
03 Jun 2019
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Bulgaria: 151
|
||
Country: Number of subjects enrolled |
Czechia: 16
|
||
Country: Number of subjects enrolled |
Estonia: 24
|
||
Country: Number of subjects enrolled |
Georgia: 191
|
||
Country: Number of subjects enrolled |
Hungary: 45
|
||
Country: Number of subjects enrolled |
Latvia: 66
|
||
Country: Number of subjects enrolled |
Moldova, Republic of: 24
|
||
Country: Number of subjects enrolled |
Poland: 71
|
||
Country: Number of subjects enrolled |
Romania: 104
|
||
Country: Number of subjects enrolled |
Russian Federation: 196
|
||
Country: Number of subjects enrolled |
Serbia: 166
|
||
Country: Number of subjects enrolled |
Slovakia: 39
|
||
Country: Number of subjects enrolled |
South Africa: 17
|
||
Country: Number of subjects enrolled |
Ukraine: 249
|
||
Country: Number of subjects enrolled |
United States: 13
|
||
Worldwide total number of subjects |
1372
|
||
EEA total number of subjects |
516
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
774
|
||
From 65 to 84 years |
556
|
||
85 years and over |
42
|
|
|||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||
Recruitment details |
Subjects took part in the study at 95 study centers in Bulgaria, Czech Republic, Estonia, Georgia, Hungary, Latvia, Moldova, Poland, Romania, Russia, Serbia, Slovakia, South Africa, Ukraine, and the United States from 03 June 2019 to 27 May 2020. | ||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||
Screening details |
Subjects with diagnosis of complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) were enrolled to receive TBPM-PI-HBr and Ertapenem. | ||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator, Carer, Assessor | ||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||
Arm title
|
TBPM-PI-HBr 600 mg | ||||||||||||||||||||||||||||||
Arm description |
TBPM-PI-HBr 600 mg (300 mg × 2 ) film-coated tablets, administered orally three times per day (every 8 hours [q8h] ± 0.5 h) plus a single dummy IV infusion over 30 minutes (min) once daily (every 24 hours [q24h] ± 0.5 h) up to Day 15; participants with moderate renal insufficiency (creatinine clearance [CrCl] >30 to ≤50 mL/min) required TBPM-PI-HBr dosage adjustment to 300 mg (one tablet) q8h ± 0.5 h. | ||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
SPR994
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
TBPM-PI-HBr 600 mg (300 mg × 2) film-coated tablet administered orally every 8 hours (q8h), per day for up to Day 14.
|
||||||||||||||||||||||||||||||
Arm title
|
Ertapenem 1g | ||||||||||||||||||||||||||||||
Arm description |
Ertapenem for IV injection, administered as a 1-gram IV infusion over 30 min once daily (q24h ± 0.5 h) plus dummy placebo tablets administered orally q8h (±0.5 h) up to Day 14; no dose adjustment of ertapenem was required for participants with renal insufficiency. | ||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Ertapenem
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
Ertapenem 1 g IV infusion administered over 30 min once daily (QD) for up to Day 14.
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
Notes [1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left. Justification: Micro-ITT=all randomized participants with a confirmed diagnosis of cUTI or AP and a positive Screening urine culture defined as growth of one or two uropathogens at ≥10^5 CFU/mL and/or positive Screening blood culture with isolation of one or more uropathogens. [2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left. Justification: Micro-ITT=all randomized participants with a confirmed diagnosis of cUTI or AP and a positive Screening urine culture defined as growth of one or two uropathogens at ≥10^5 CFU/mL and/or positive Screening blood culture with isolation of one or more uropathogens. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
TBPM-PI-HBr 600 mg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
TBPM-PI-HBr 600 mg (300 mg × 2 ) film-coated tablets, administered orally three times per day (every 8 hours [q8h] ± 0.5 h) plus a single dummy IV infusion over 30 minutes (min) once daily (every 24 hours [q24h] ± 0.5 h) up to Day 15; participants with moderate renal insufficiency (creatinine clearance [CrCl] >30 to ≤50 mL/min) required TBPM-PI-HBr dosage adjustment to 300 mg (one tablet) q8h ± 0.5 h. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Ertapenem 1g
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Ertapenem for IV injection, administered as a 1-gram IV infusion over 30 min once daily (q24h ± 0.5 h) plus dummy placebo tablets administered orally q8h (±0.5 h) up to Day 14; no dose adjustment of ertapenem was required for participants with renal insufficiency. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
TBPM-PI-HBr 600 mg
|
||
Reporting group description |
TBPM-PI-HBr 600 mg (300 mg × 2 ) film-coated tablets, administered orally three times per day (every 8 hours [q8h] ± 0.5 h) plus a single dummy IV infusion over 30 minutes (min) once daily (every 24 hours [q24h] ± 0.5 h) up to Day 15; participants with moderate renal insufficiency (creatinine clearance [CrCl] >30 to ≤50 mL/min) required TBPM-PI-HBr dosage adjustment to 300 mg (one tablet) q8h ± 0.5 h. | ||
Reporting group title |
Ertapenem 1g
|
||
Reporting group description |
Ertapenem for IV injection, administered as a 1-gram IV infusion over 30 min once daily (q24h ± 0.5 h) plus dummy placebo tablets administered orally q8h (±0.5 h) up to Day 14; no dose adjustment of ertapenem was required for participants with renal insufficiency. |
|
||||||||||
End point title |
Overall Response (Combined Clinical Cure and Microbiological Eradication) at Test-of-Cure (TOC) in Micro Intent-to-Treat Population | |||||||||
End point description |
Overall response is participants with combined clinical cure and microbiological eradication. Clinical cure is defined as complete resolution or significant improvement of signs and symptoms of cUTI or AP that were present at baseline and no new symptoms, such that no further antimicrobial therapy is warranted. Microbiological eradication is defined as reduction of Baseline urine pathogen(s) to <10^3 colony forming unit/milliliter (CFU/mL) and negative repeated blood culture if blood culture was positive for uropathogen growth at Baseline. Microbiological intent-to-treat population (Micro-ITT) included all randomized subjects with a confirmed diagnosis of cUTI or AP and a positive Screening urine culture defined as growth of one or two uropathogens at ≥10^5 CFU/mL and/or positive Screening blood culture with isolation of one or more uropathogens.
|
|||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
Day 19 (TOC)
|
|||||||||
|
||||||||||
Statistical analysis title |
Statistical Analysis 1 | |||||||||
Comparison groups |
TBPM-PI-HBr 600 mg v Ertapenem 1g
|
|||||||||
Number of subjects included in analysis |
868
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
non-inferiority [1] | |||||||||
Method |
||||||||||
Parameter type |
Risk Difference | |||||||||
Point estimate |
-3.3
|
|||||||||
Confidence interval |
||||||||||
level |
95% | |||||||||
sides |
2-sided
|
|||||||||
lower limit |
-9.7 | |||||||||
upper limit |
3.2 | |||||||||
Notes [1] - The non-inferiority hypothesis test was a 1-sided hypothesis test performed at the 2.5% level of significance. If the lower limit of the 95% CI for the difference in overall response was greater than -12.5%, non-inferiority was declared. |
|
||||||||||
End point title |
Number of Subjects With Treatment Emergent Adverse Events (TEAEs) in The Safety Population [2] | |||||||||
End point description |
An Adverse Event (AE) was defined as any untoward medical occurrence in a subject or clinical investigation participant administered a pharmaceutical product, which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational/experimental) product, whether or not related to this product. Safety analysis population included all randomized subjects who received any amount of study drug.
|
|||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
From the first dose of administration up to Day 25 post-treatment ± 2 days (up to approximately 27 days)
|
|||||||||
Notes [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analyses have been specified for this end point. |
||||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Overall Response (Combined Clinical Cure Plus Microbiological Eradication) At Test-Of-Cure (TOC) In The Microbiologically Evaluable (ME) - TOC Population | |||||||||
End point description |
Overall response is number of subjects with combined clinical cure and microbiological eradication. Clinical cure is defined as complete resolution or significant improvement of signs and symptoms of cUTI or AP that were present at baseline and no new symptoms, such that no further antimicrobial therapy is warranted. Microbiological eradication is defined as reduction of Baseline urine pathogen(s) to <10^3 CFU/mL and negative repeated blood culture if blood culture was positive for uropathogen growth at Baseline. Microbiologically evaluable (ME) - TOC population included subjects who met the definitions of both the micro-ITT Population and CE Population and were defined for each visit for the analyses in the ME Population at each respective visit as outlined in the evaluability review plan (ERP).
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Day 19 (TOC)
|
|||||||||
|
||||||||||
Statistical analysis title |
Statistical Analysis 1 | |||||||||
Comparison groups |
Ertapenem 1g v TBPM-PI-HBr 600 mg
|
|||||||||
Number of subjects included in analysis |
789
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
other | |||||||||
Method |
||||||||||
Parameter type |
Risk Difference | |||||||||
Point estimate |
-4.7
|
|||||||||
Confidence interval |
||||||||||
level |
95% | |||||||||
sides |
2-sided
|
|||||||||
lower limit |
-11.3 | |||||||||
upper limit |
1.9 |
|
|||||||||||||||||||
End point title |
Clinical Cure at End-of-Treatment (EOT), TOC, and Sustained Clinical Cure at Late Follow-Up (LFU) in the Micro-ITT Population | ||||||||||||||||||
End point description |
Clinical cure is defined as number of subjects with complete resolution or significant improvement of signs and symptoms of cUTI or AP that were present at Baseline and no new symptoms, such that no further antimicrobial therapy is warranted. Sustained clinical cure is defined as subjects who wet criteria for clinical cure at TOC and remained free of signs and symptoms of cUTI or AP at LFU. Micro-ITT included all randomized subjects with a confirmed diagnosis of cUTI or AP and a positive Screening urine culture defined as growth of one or two uropathogens at ≥10^5 CFU/mL and/or positive Screening blood culture with isolation of one or more uropathogens.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Days 15 (EOT), Day 19 (TOC) and Day 25 (LFU)
|
||||||||||||||||||
|
|||||||||||||||||||
Statistical analysis title |
Statistical Analysis 1 (EOT) | ||||||||||||||||||
Comparison groups |
TBPM-PI-HBr 600 mg v Ertapenem 1g
|
||||||||||||||||||
Number of subjects included in analysis |
868
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
other | ||||||||||||||||||
Method |
|||||||||||||||||||
Parameter type |
Risk Difference | ||||||||||||||||||
Point estimate |
1.4
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
-0.1 | ||||||||||||||||||
upper limit |
3.4 | ||||||||||||||||||
Statistical analysis title |
Statistical Analysis 3 (LFU) | ||||||||||||||||||
Comparison groups |
TBPM-PI-HBr 600 mg v Ertapenem 1g
|
||||||||||||||||||
Number of subjects included in analysis |
868
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
other | ||||||||||||||||||
Method |
|||||||||||||||||||
Parameter type |
Risk Difference | ||||||||||||||||||
Point estimate |
-1.5
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
-5.7 | ||||||||||||||||||
upper limit |
2.6 | ||||||||||||||||||
Statistical analysis title |
Statistical Analysis 2 (TOC) | ||||||||||||||||||
Comparison groups |
TBPM-PI-HBr 600 mg v Ertapenem 1g
|
||||||||||||||||||
Number of subjects included in analysis |
868
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
other | ||||||||||||||||||
Method |
|||||||||||||||||||
Parameter type |
Risk Difference | ||||||||||||||||||
Point estimate |
-0.6
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
-4 | ||||||||||||||||||
upper limit |
2.8 |
|
||||||||||
End point title |
Clinical Cure at EOT in the Clinically Evaluable (CE-EOT) Population | |||||||||
End point description |
Clinical cure is defined as number of subjects with complete resolution or significant improvement of signs and symptoms of cUTI or AP that were present at Baseline and no new symptoms, such that no further antimicrobial therapy is warranted. CE-EOT population is a subset which included subjects who meet the definition for the ITT population, have no important protocol deviations that would affect the assessment of efficacy, and had an outcome assessed as clinical cure or clinical failure at EOT.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Day 15 (EOT)
|
|||||||||
|
||||||||||
Statistical analysis title |
Statistical Analysis 1 | |||||||||
Comparison groups |
TBPM-PI-HBr 600 mg v Ertapenem 1g
|
|||||||||
Number of subjects included in analysis |
1351
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
other | |||||||||
Method |
||||||||||
Parameter type |
Risk Difference | |||||||||
Point estimate |
0.7
|
|||||||||
Confidence interval |
||||||||||
level |
95% | |||||||||
sides |
2-sided
|
|||||||||
lower limit |
-0.3 | |||||||||
upper limit |
2 |
|
||||||||||
End point title |
Clinical Cure at TOC in the CE-TOC Populations | |||||||||
End point description |
Clinical cure is defined as number of subjects with complete resolution or significant improvement of signs and symptoms of cUTI or AP that were present at baseline and no new symptoms, such that no further antimicrobial therapy is warranted. CE-TOC population is a subset which included participants who meet the definition for the ITT population, have no important protocol deviations that would affect the assessment of efficacy, and had an outcome assessed as clinical cure or clinical failure at TOC.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Day 19 (TOC)
|
|||||||||
|
||||||||||
Statistical analysis title |
Statistical Analysis 1 | |||||||||
Comparison groups |
TBPM-PI-HBr 600 mg v Ertapenem 1g
|
|||||||||
Number of subjects included in analysis |
1278
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
other | |||||||||
Method |
||||||||||
Parameter type |
Risk Difference | |||||||||
Point estimate |
-1.6
|
|||||||||
Confidence interval |
||||||||||
level |
95% | |||||||||
sides |
2-sided
|
|||||||||
lower limit |
-3.8 | |||||||||
upper limit |
0.6 |
|
||||||||||
End point title |
Sustained Clinical Cure at LFU in the CE-LFU Population | |||||||||
End point description |
Clinical cure is defined as number of subjects with complete resolution or significant improvement of signs and symptoms of cUTI or AP that were present at baseline and no new symptoms, such that no further antimicrobial therapy is warranted. Sustained clinical cure is defined as participants who met criteria for clinical cure at TOC and remained free of signs and symptoms of cUTI or AP at LFU. CE-LFU population is a subset which included subjects who meet the definition for the ITT population, have no important protocol deviations that would affect the assessment of efficacy, and had an outcome assessed as clinical cure or clinical failure at LFU.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Day 25 (LFU)
|
|||||||||
|
||||||||||
Statistical analysis title |
Statistical Analysis 1 | |||||||||
Comparison groups |
TBPM-PI-HBr 600 mg v Ertapenem 1g
|
|||||||||
Number of subjects included in analysis |
1192
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
other | |||||||||
Method |
||||||||||
Parameter type |
Risk Difference | |||||||||
Point estimate |
-0.5
|
|||||||||
Confidence interval |
||||||||||
level |
95% | |||||||||
sides |
2-sided
|
|||||||||
lower limit |
-3.3 | |||||||||
upper limit |
2.3 |
|
||||||||||
End point title |
Clinical Cure at EOT in the ME-EOT Population | |||||||||
End point description |
Clinical cure is defined as number of participants with complete resolution or significant improvement of signs and symptoms of cUTI or AP that were present at Baseline and no new symptoms, such that no further antimicrobial therapy is warranted. ME-EOT population is a subset which included subjects who met the definitions of both the micro-ITT Population and CE Population and were defined for each visit for the analyses in the ME Population at each respective visit as outlined in the ERP.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Day 15 (EOT)
|
|||||||||
|
||||||||||
Statistical analysis title |
Statistical Analysis 1 | |||||||||
Comparison groups |
TBPM-PI-HBr 600 mg v Ertapenem 1g
|
|||||||||
Number of subjects included in analysis |
840
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
other | |||||||||
Method |
||||||||||
Parameter type |
Risk Difference | |||||||||
Point estimate |
1.3
|
|||||||||
Confidence interval |
||||||||||
level |
95% | |||||||||
sides |
2-sided
|
|||||||||
lower limit |
-0.2 | |||||||||
upper limit |
3.2 |
|
||||||||||
End point title |
Clinical Cure at TOC in the ME-TOC Population | |||||||||
End point description |
Clinical cure is defined as number of participants with complete resolution or significant improvement of signs and symptoms of cUTI or AP that were present at Baseline and no new symptoms, such that no further antimicrobial therapy is warranted. ME-TOC population is a subset which included subjects who met the definitions of both the micro-ITT Population and CE Population and were defined for each visit for the analyses in the ME Population at each respective visit as outlined in the ERP.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Day 19 (TOC)
|
|||||||||
|
||||||||||
Statistical analysis title |
Statistical Analysis 1 | |||||||||
Comparison groups |
TBPM-PI-HBr 600 mg v Ertapenem 1g
|
|||||||||
Number of subjects included in analysis |
789
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
other | |||||||||
Method |
||||||||||
Parameter type |
Risk Difference | |||||||||
Point estimate |
-2.2
|
|||||||||
Confidence interval |
||||||||||
level |
95% | |||||||||
sides |
2-sided
|
|||||||||
lower limit |
-5.3 | |||||||||
upper limit |
0.8 |
|
||||||||||
End point title |
Sustained Clinical Cure at LFU in the ME-LFU Population | |||||||||
End point description |
Clinical cure is defined as number of participants with complete resolution or significant improvement of signs and symptoms of cUTI or AP that were present at Baseline and no new symptoms, such that no further antimicrobial therapy is warranted. Sustained clinical cure is defined as participants who met criteria for clinical cure at TOC and remained free of signs and symptoms of cUTI or AP at LFU. ME-LFU population is a subset which included subjects who met the definitions of both the micro-ITT Population and CE Population and were defined for each visit for the analyses in the ME Population at each respective visit as outlined in the ERP.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Day 25 (LFU)
|
|||||||||
|
||||||||||
Statistical analysis title |
Statistical Analysis 1 | |||||||||
Comparison groups |
TBPM-PI-HBr 600 mg v Ertapenem 1g
|
|||||||||
Number of subjects included in analysis |
744
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
other | |||||||||
Method |
||||||||||
Parameter type |
Risk Difference | |||||||||
Point estimate |
-1.2
|
|||||||||
Confidence interval |
||||||||||
level |
95% | |||||||||
sides |
2-sided
|
|||||||||
lower limit |
-5.1 | |||||||||
upper limit |
2.6 |
|
|||||||||||||||||||
End point title |
By-Patient Microbiological Eradication at EOT, TOC, Sustained Microbiological Eradication at LFU in the Micro-ITT Population | ||||||||||||||||||
End point description |
Microbiological eradication is defined as reduction of baseline urine pathogen(s) to <10^3 colony forming unit/milliliter (CFU/mL) and negative repeated blood culture if blood culture was positive for uropathogen growth at baseline. Sustained Microbiological Eradication is defined subjects with microbiologic eradication at the TOC and no subsequent urine culture after TOC demonstrating recurrence of the original baseline uropathogen at ≥10^5 CFU/mL. Micro-ITT include all randomized subjects with a confirmed diagnosis of cUTI or AP and a positive Screening urine culture defined as growth of one or two uropathogens at ≥10^5 CFU/mL and/or positive Screening blood culture with isolation of one or more uropathogens.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Days 15 (EOT), 19 (TOC) and 25 (LFU)
|
||||||||||||||||||
|
|||||||||||||||||||
Statistical analysis title |
Statistical Analysis 1 (EOT) | ||||||||||||||||||
Comparison groups |
TBPM-PI-HBr 600 mg v Ertapenem 1g
|
||||||||||||||||||
Number of subjects included in analysis |
868
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
other | ||||||||||||||||||
Method |
|||||||||||||||||||
Parameter type |
Risk Difference | ||||||||||||||||||
Point estimate |
1.5
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
-0.8 | ||||||||||||||||||
upper limit |
4.1 | ||||||||||||||||||
Statistical analysis title |
Copy of Statistical Analysis 3 (LFU) | ||||||||||||||||||
Comparison groups |
TBPM-PI-HBr 600 mg v Ertapenem 1g
|
||||||||||||||||||
Number of subjects included in analysis |
868
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
other | ||||||||||||||||||
Method |
|||||||||||||||||||
Parameter type |
Risk Difference | ||||||||||||||||||
Point estimate |
-1.5
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
-7.9 | ||||||||||||||||||
upper limit |
5 | ||||||||||||||||||
Statistical analysis title |
Statistical Analysis 2 (TOC) | ||||||||||||||||||
Comparison groups |
TBPM-PI-HBr 600 mg v Ertapenem 1g
|
||||||||||||||||||
Number of subjects included in analysis |
868
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
other | ||||||||||||||||||
Method |
|||||||||||||||||||
Parameter type |
Risk Difference | ||||||||||||||||||
Point estimate |
-4.5
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
-10.8 | ||||||||||||||||||
upper limit |
1.9 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
By-Pathogen Microbiological Eradication Rate at EOT in the Micro-ITT Populations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Microbiological eradication rate is percentage of participants with microbiological eradication. Microbiological eradication is defined as reduction of Baseline urine pathogen(s) to <10^3 CFU/mL and negative repeated blood culture if blood culture was positive for uropathogen growth at baseline. Micro-ITT included all randomized subjects with a confirmed diagnosis of cUTI or AP and a positive Screening urine culture defined as growth of one or two uropathogens at ≥10^5 CFU/mL and/or positive Screening blood culture with isolation of one/more uropathogens. Microbiological eradication rate is percentage of pathogens being eradicated from overall number of pathogens analyzed. 'n' = Number analyzed is number of pathogens analyzed at the given timepoint.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 15 (EOT)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
By-Pathogen Microbiological Eradication Rate at TOC in the Micro-ITT Populations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Microbiological eradication rate is percentage of participants with microbiological eradication. Microbiological eradication is defined as reduction of Baseline urine pathogen(s) to <10^3 CFU/mL and negative repeated blood culture if blood culture was positive for uropathogen growth at baseline. Micro-ITT included all randomized subjects with a confirmed diagnosis of cUTI or AP and a positive Screening urine culture defined as growth of one or two uropathogens at ≥10^5 CFU/mL and/or positive Screening blood culture with isolation of one/more uropathogens. Microbiological eradication rate is percentage of pathogens being eradicated from overall number of subjects analyzed. 'n' = Number analyzed is number of pathogens analyzed at the given timepoint.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Days 19 (TOC)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
By-Pathogen Sustained Microbiological Eradication Rate at LFU in the Micro-ITT Populations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Microbiological eradication rate is percentage of participants with microbiological eradication. Microbiological eradication is defined as reduction of Baseline urine pathogen(s) to <10^3 CFU/mL and negative repeated blood culture if blood culture was positive for uropathogen growth at baseline. Sustained Microbiological Eradication is defined participants with microbiologic eradication at the TOC and no subsequent urine culture after TOC demonstrating recurrence of the original baseline uropathogen at ≥10^5 CFU/mL. Micro-ITT included all randomized subjects with a confirmed diagnosis of cUTI or AP and a positive Screening urine culture defined as growth of one or two uropathogens at ≥10^5 CFU/mL and/or positive Screening blood culture with isolation of one or more uropathogens. 'n' = Number analyzed is number of pathogens analyzed at the given timepoint.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Days 25 (LFU)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
By-Patient Microbiological Eradication at EOT in the ME-EOT Population | |||||||||
End point description |
Microbiological eradication is defined as number of participants with reduction of Baseline urine pathogen(s) to <10^3 CFU/mL and negative repeated blood culture if blood culture was positive for uropathogen growth at Baseline. ME-EOT population is a subset which included subjects who met the definitions of both the micro-ITT Population and CE Population and were defined for each visit for the analyses in the ME Population at each respective visit as outlined in the ERP.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Day 15 (EOT)
|
|||||||||
|
||||||||||
Statistical analysis title |
Statistical Analysis 1 | |||||||||
Comparison groups |
TBPM-PI-HBr 600 mg v Ertapenem 1g
|
|||||||||
Number of subjects included in analysis |
840
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
other | |||||||||
Method |
||||||||||
Parameter type |
Risk Difference | |||||||||
Point estimate |
-0.2
|
|||||||||
Confidence interval |
||||||||||
level |
95% | |||||||||
sides |
2-sided
|
|||||||||
lower limit |
-1.6 | |||||||||
upper limit |
1.2 |
|
||||||||||
End point title |
By-Patient Microbiological Eradication at TOC in the ME-TOC Population | |||||||||
End point description |
Microbiological eradication is defined as number of participants with reduction of Baseline urine pathogen(s) to <10^3 CFU/mL and negative repeated blood culture if blood culture was positive for uropathogen growth at Baseline. ME-TOC population is a subset which included subjects who met the definitions of both the micro-ITT Population and CE Population and were defined for each visit for the analyses in the ME Population at each respective visit as outlined in the ERP.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Day 19 (TOC)
|
|||||||||
|
||||||||||
Statistical analysis title |
Statistical Analysis 1 | |||||||||
Comparison groups |
TBPM-PI-HBr 600 mg v Ertapenem 1g
|
|||||||||
Number of subjects included in analysis |
789
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
other | |||||||||
Method |
||||||||||
Parameter type |
Risk Difference | |||||||||
Point estimate |
-5.9
|
|||||||||
Confidence interval |
||||||||||
level |
95% | |||||||||
sides |
2-sided
|
|||||||||
lower limit |
-12.4 | |||||||||
upper limit |
0.7 |
|
||||||||||
End point title |
By-Patient Sustained Microbiological Eradication at LFU in the ME-LFU Population | |||||||||
End point description |
Microbiological eradication is defined as number of participants with reduction of Baseline urine pathogen(s) to <10^3 CFU/mL and negative repeated blood culture if blood culture was positive for uropathogen growth at Baseline. Sustained Microbiological Eradication is defined participants with microbiologic eradication at the TOC and no subsequent urine culture after TOC demonstrating recurrence of the original baseline uropathogen at ≥10^5 CFU/mL. Sustained Microbiological Eradication is defined participants with microbiologic eradication at the TOC and no subsequent urine culture after TOC demonstrating recurrence of the original baseline uropathogen at ≥10^5 CFU/mL. ME-LFU population included subjects who met the definitions of both the micro-ITT Population and CE Population and were defined for each visit for the analyses in the ME Population at each respective visit as outlined in the ERP. Number analyzed is number of pathogens analyzed at the given timepoint.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Day 25 (LFU)
|
|||||||||
|
||||||||||
Statistical analysis title |
Statistical Analysis 1 | |||||||||
Comparison groups |
Ertapenem 1g v TBPM-PI-HBr 600 mg
|
|||||||||
Number of subjects included in analysis |
744
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
other | |||||||||
Method |
||||||||||
Parameter type |
Risk Difference | |||||||||
Point estimate |
-1.6
|
|||||||||
Confidence interval |
||||||||||
level |
95% | |||||||||
sides |
2-sided
|
|||||||||
lower limit |
-8.5 | |||||||||
upper limit |
5.3 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
By-pathogen Microbiological Eradication Rate at EOT in the ME-EOT Population | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Microbiological eradication is defined as percentage of participants with reduction of Baseline urine pathogen(s) to <10^3 CFU/mL and negative repeated blood culture if blood culture was positive for uropathogen growth at Baseline. ME-EOT population is a subset which included subjects who met the definitions of both the micro-ITT Population and CE Population and were defined for each visit for the analyses in the ME Population at each respective visit as outlined in the ERP. Microbiological eradication rate is the percentage of pathogens being eradicated from the overall number of pathogens analyzed. Overall number of subjects analysed are the subjects with data available for analysis. 'n' = Number analyzed is number of pathogens analyzed at the given timepoint.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 15 (EOT)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
By-pathogen Microbiological Eradication Rate at TOC in the ME-TOC Populations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Microbiological eradication is defined as reduction of Baseline urine pathogen(s) to <10^3 CFU/mL and negative repeated blood culture if blood culture was positive for uropathogen growth at Baseline. ME-TOC population is a subset which included subjects who met the definitions of both the micro-ITT Population and CE Population and were defined for each visit for the analyses in the ME Population at each respective visit as outlined in the ERP. Microbiological eradication rate is the percentage of pathogens being eradicated from the overall number of pathogens analyzed. 'n' = Number analyzed is number of pathogens analyzed at the given timepoint.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 19 (TOC)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
By-pathogen Sustained Microbiological Eradication at LFU in the ME-LFU Populations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Microbiological eradication is defined as percentage of participants with reduction of Baseline urine pathogen(s) to <10^3 CFU/mL and negative repeated blood culture if blood culture was positive for uropathogen growth at Baseline. Sustained Microbiological Eradication is defined participants with microbiologic eradication at the TOC and no subsequent urine culture after TOC demonstrating recurrence of the original baseline uropathogen at ≥10^5 CFU/mL. ME population included subjects who met the definitions of both the micro-ITT Population and CE Population and were defined for each visit for the analyses in the ME Population at each respective visit as outlined in the ERP. Microbiological eradication rate is the percentage of pathogens being eradicated from the overall number of pathogens analyzed. 'n' = Number analyzed is number of pathogens analyzed at the given timepoint.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 25 (LFU)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Overall Response Rate (Combined Clinical Cure Plus Microbiological Eradication) at TOC In Subgroup Including: Stratified Infection Category | ||||||||||||||||||
End point description |
Overall response rate is percentage of participants with combined clinical cure plus microbiological eradication. Clinical cure is defined as complete resolution or significant improvement of signs and symptoms of cUTI or AP that were present at Baseline and no new symptoms, such that no further antimicrobial therapy is warranted. Microbiological eradication is defined as reduction of Baseline urine pathogen(s) to <10^3 CFU/mL and negative repeated blood culture if blood culture was positive for uropathogen growth at Baseline. Micro-ITT population included all randomized subjects with a confirmed diagnosis of cUTI or AP and a positive Screening urine culture defined as growth of one or two uropathogens at ≥105 CFU/mL and/or positive Screening blood culture with isolation of one or more uropathogens. n=number analyzed is the number of participants with data available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Day 19 (TOC)
|
||||||||||||||||||
|
|||||||||||||||||||
Statistical analysis title |
Statistical Analysis 1 (AP) | ||||||||||||||||||
Comparison groups |
TBPM-PI-HBr 600 mg v Ertapenem 1g
|
||||||||||||||||||
Number of subjects included in analysis |
868
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
other | ||||||||||||||||||
Method |
|||||||||||||||||||
Parameter type |
Risk Difference | ||||||||||||||||||
Point estimate |
-4.7
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
-13.5 | ||||||||||||||||||
upper limit |
4.1 | ||||||||||||||||||
Statistical analysis title |
Statistical Analysis 2 (cUTI) | ||||||||||||||||||
Comparison groups |
TBPM-PI-HBr 600 mg v Ertapenem 1g
|
||||||||||||||||||
Number of subjects included in analysis |
868
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
other | ||||||||||||||||||
Method |
|||||||||||||||||||
Parameter type |
Risk Difference | ||||||||||||||||||
Point estimate |
-1.6
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
-11 | ||||||||||||||||||
upper limit |
7.7 |
|
||||||||||||||||||||||
End point title |
Overall Response Rate (Combined Clinical Cure Plus Microbiological Eradication) at TOC In Subgroup Stratified Age Category | |||||||||||||||||||||
End point description |
Overall response rate is percentage of participants with combined clinical cure plus microbiological eradication. Clinical cure is defined as complete resolution or significant improvement of signs and symptoms of cUTI or AP that were present at baseline and no new symptoms, such that no further antimicrobial therapy is warranted. Microbiological eradication is defined as reduction of baseline urine pathogen(s) to <10^3 CFU/mL and negative repeated blood culture if blood culture was positive for uropathogen growth at baseline. Micro-ITT population included all randomized participants with a confirmed diagnosis of cUTI or AP and a positive Screening urine culture defined as growth of one or two uropathogens at ≥105 CFU/mL and/or positive Screening blood culture with isolation of one or more uropathogens. 'n' indicated number analysed is number of participants with data available for analysis at specific timepoint.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
Day 19 (TOC)
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Statistical analysis title |
Statistical Analysis 1 (≥18 to <65 years) | |||||||||||||||||||||
Comparison groups |
TBPM-PI-HBr 600 mg v Ertapenem 1g
|
|||||||||||||||||||||
Number of subjects included in analysis |
868
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
other | |||||||||||||||||||||
Method |
||||||||||||||||||||||
Parameter type |
Risk Difference | |||||||||||||||||||||
Point estimate |
1.4
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
-7.2 | |||||||||||||||||||||
upper limit |
9.9 | |||||||||||||||||||||
Statistical analysis title |
Statistical Analysis 2 (≥65 to <75 years) | |||||||||||||||||||||
Comparison groups |
TBPM-PI-HBr 600 mg v Ertapenem 1g
|
|||||||||||||||||||||
Number of subjects included in analysis |
868
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
other | |||||||||||||||||||||
Method |
||||||||||||||||||||||
Parameter type |
Risk Difference | |||||||||||||||||||||
Point estimate |
-8.4
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
-20.6 | |||||||||||||||||||||
upper limit |
3.8 | |||||||||||||||||||||
Statistical analysis title |
Statistical Analysis 3 (≥75 years ) | |||||||||||||||||||||
Comparison groups |
TBPM-PI-HBr 600 mg v Ertapenem 1g
|
|||||||||||||||||||||
Number of subjects included in analysis |
868
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
other | |||||||||||||||||||||
Method |
||||||||||||||||||||||
Parameter type |
Risk Difference | |||||||||||||||||||||
Point estimate |
-7.5
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
-23.8 | |||||||||||||||||||||
upper limit |
8.7 |
|
||||||||||||||||||||||
End point title |
Overall Response Rate (Combined Clinical Cure Plus Microbiological Eradication) at TOC In Subgroup Including Region | |||||||||||||||||||||
End point description |
Overall response rate is percentage of participants with combined clinical cure plus microbiological eradication. Clinical cure is defined as complete resolution or significant improvement of signs and symptoms of cUTI or AP that were present at Baseline and no new symptoms, such that no further antimicrobial therapy is warranted. Microbiological eradication is defined as reduction of Baseline urine pathogen(s) to <10^3 CFU/mL and negative repeated blood culture if blood culture was positive for uropathogen growth at Baseline. Micro-ITT included all randomized subjects with a confirmed diagnosis of cUTI or AP and a positive Screening urine culture defined as growth of one or two uropathogens at ≥10^5 CFU/mL and/or positive Screening blood culture with isolation of one or more uropathogens. Number analyzed is number of subjects with data available for analysis at specific timepoint. ‘The point estimate and confidence interval (CI) presented is for Central and eastern Europe subgroup’
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
Day 25 (TOC)
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Statistical analysis title |
Statistical Analysis 1- Central and Eastern Europe | |||||||||||||||||||||
Comparison groups |
TBPM-PI-HBr 600 mg v Ertapenem 1g
|
|||||||||||||||||||||
Number of subjects included in analysis |
868
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
other | |||||||||||||||||||||
Method |
||||||||||||||||||||||
Parameter type |
Risk Difference | |||||||||||||||||||||
Point estimate |
-3.1
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
-9.6 | |||||||||||||||||||||
upper limit |
3.5 |
|
|||||||||||||
End point title |
Time (Days) to Resolution or Improvement of Signs and Symptoms of cUTI and AP Present a Baseline in the Micro-ITT Populations | ||||||||||||
End point description |
Time (days) to resolution or improvement of signs and symptoms of cUTI and AP present at baseline was defined as follows: date of the first visit at which all baseline signs/symptoms have improved by at least 1 grade with worsening of none and development of no new signs/symptoms of the index infection minus the date of randomization. Micro-ITT population included all randomized subjects with a confirmed diagnosis of cUTI or AP and a positive Screening urine culture defined as growth of one or two uropathogens at ≥10^5 CFU/mL and/or positive Screening blood culture with isolation of one or more uropathogens.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 25 (LFU)
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Statistical Analysis 1 | ||||||||||||
Comparison groups |
TBPM-PI-HBr 600 mg v Ertapenem 1g
|
||||||||||||
Number of subjects included in analysis |
868
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other | ||||||||||||
P-value |
= 0.044 | ||||||||||||
Method |
Logrank | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
Time (Days) to Defervescence in Micro-ITT Population With a Documented Fever at Screening or Day 1 | ||||||||||||
End point description |
Time to Defervescence (days) = date of first post-baseline temperature measure with maximum daily temperature ≤38°C at the date of randomization. Micro-ITT population included all randomized subjects with a confirmed diagnosis of cUTI or AP and a positive Screening urine culture defined as growth of one or two uropathogens at ≥10^5 CFU/mL and/or positive Screening blood culture with isolation of one or more uropathogens. Overall number of subjects analysed are the subjects with data available for analysis.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 25 (LFU)
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Statistical Analysis 1 | ||||||||||||
Comparison groups |
Ertapenem 1g v TBPM-PI-HBr 600 mg
|
||||||||||||
Number of subjects included in analysis |
419
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other | ||||||||||||
P-value |
= 0.736 | ||||||||||||
Method |
Logrank | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
Rate of Clinical Relapse at the LFU in the Micro-ITT Population | ||||||||||||
End point description |
Clinical relapse is subjects who met criteria for clinical cure at TOC, but new signs and symptoms of cUTI or AP are present at the LFU Visit and the subject requires antibiotic therapy for the cUT. Clinical cure is defined as complete resolution or significant improvement of signs and symptoms of cUTI or AP that were present at baseline and no new symptoms, such that no further antimicrobial therapy is warranted. Micro-ITT population included all randomized subjects with a confirmed diagnosis of cUTI or AP and a positive Screening urine culture defined as growth of one or two uropathogens at ≥10^5 CFU/mL and/or positive Screening blood culture with isolation of one or more uropathogens.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 25 (LFU)
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Rates of Superinfection And New Infection In The Micro-ITT Population | ||||||||||||||||||
End point description |
Superinfection was isolation of a new uropathogen at ≥10^5 CFU/mL (other than original Baseline pathogen from blood and/or urine) from a urine culture that was accompanied by clinical signs and symptoms of infection requiring alternative antimicrobial therapy (e.g., the participant was assessed by the investigator as a clinical failure) during the period up to and including EOT. New infection was isolation of new uropathogen at ≥105 CFU/mL (other than the original baseline pathogen from blood and/or urine) from a urine culture that was accompanied by clinical signs symptoms of infection requiring alternative antimicrobial therapy in the period after EOT. Micro-ITT population included all randomized subjects with a confirmed diagnosis of cUTI or AP and a positive Screening urine culture defined as growth of one or two uropathogens at ≥10^5 CFU/mL and/or positive Screening blood culture with isolation of one or more uropathogens.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Day 25 (LFU)
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Apparent Volume of Distribution (Vss) at Steady State in TBPM-PI-HBr Recipients in the PK Population [3] | ||||||||||||
End point description |
PK population included subjects treated with at least 1 dose of TBPM-PI-HBr with at least 1 analyzable plasma or urine PK sample.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Predose and post-dose at 0.25h, 0.5h, 1h, 2h, and 8h on Days 1 and 3
|
||||||||||||
Notes [3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: No statistical analyses have been specified for this end point. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Cmax in TBPM-PI-HBr Recipients in the PK Population [4] | ||||||||||||
End point description |
PK population included subjects treated with at least 1 dose of TBPM-PI-HBr with at least 1 analyzable plasma or urine PK sample. The data is reported only for TBPM-PI-HBr arm.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Predose and post-dose at 0.25h, 0.5h, 1h, 2h, and 8h on Days 1 and 3
|
||||||||||||
Notes [4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: No statistical analyses have been specified for this end point. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Area Under Curve (AUC 0-24) in TBPM-PI-HBr Recipients in the PK Population [5] | ||||||||||||
End point description |
PK population included subjects treated with at least 1 dose of TBPM-PI-HBr with at least 1 analyzable plasma or urine PK sample. The data is reported only for TBPM-PI-HBr arm.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Predose and post-dose on Day 1 and 3 at 1 h; 4h (±1h); and 8 h prior to the next scheduled dose
|
||||||||||||
Notes [5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: No statistical analyses have been specified for this end point. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Minimum Concentration (Cmin) in TBPM-PI-HBr Recipients in the PK Population [6] | ||||||||||||
End point description |
PK population included subjects treated with at least 1 dose of TBPM-PI-HBr with at least 1 analyzable plasma or urine PK sample. The data is reported only for TBPM-PI-HBr arm.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Predose and post-dose at 0.25h, 0.5h, 1h, 2h, and 8h on Days 1 and 3
|
||||||||||||
Notes [6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: No statistical analyses have been specified for this end point. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Systemic Clearance (CL) in TBPM-PI-HBr Recipients in the PK Population [7] | ||||||||||||
End point description |
PK population included subjects treated with at least 1 dose of TBPM-PI-HBr with at least 1 analyzable plasma or urine PK sample. The data is reported only for TBPM-PI-HBr arm.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Predose and post-dose at 0.25h, 0.5h, 1h, 2h, and 8h on Days 1 and 3
|
||||||||||||
Notes [7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: No statistical analyses have been specified for this end point. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From the first dose of administration up to Day 25 post-treatment ± 2 days (up to approximately 27 days)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Safety analysis population included all randomized participants who received any amount of study drug.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
23.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
TBPM-PI-HBr 600 mg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
TBPM-PI-HBr 600 mg (300 mg × 2 ) film-coated tablets, administered orally three times per day (every 8 hours [q8h] ± 0.5 h) plus a single dummy IV infusion over 30 minutes (min) once daily (every 24 hours [q24h] ± 0.5 h) up to Day 15; participants with moderate renal insufficiency (creatinine clearance [CrCl] >30 to ≤50 mL/min) required TBPM-PI-HBr dosage adjustment to 300 mg (one tablet) q8h ± 0.5 h. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Ertapenem 1 g
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Ertapenem for IV injection, administered as a 1-gram IV infusion over 30 min once daily (q24h ± 0.5 h) plus dummy placebo tablets administered orally q8h (±0.5 h) up to Day 14; no dose adjustment of ertapenem was required for participants with renal insufficiency. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
10 Feb 2019 |
Amendment 1: Additional information regarding the total anticipated enrollment of subjects was contingent on sufficient number of evaluable subjects. Subjects with moderate renal impairment were included with dosage adjustments. Inclusion Criterion 3 was added as additional criteria for subjects presenting with nausea and/or vomiting. Clarification of subjects populations and evaluability rates. Statement added that the planned total enrollment may be adjusted as needed to ensure sufficient data were available from 884 evaluable subjects if a change in dose was required. Clarification on reasons for IP discontinuation and subsequent EOT assessment. Additional detail were added for comparator (ertapenem) and placebo. Additional instructions were added regarding timing of IP administration, timing of IP oral medication, dosing interruptions, and missed doses. Clarification of CrCl monitoring and the process for recording the unblinding of source documents. Definition of Clinical Cure and Microbiological Eradication were updated to specify that subjects must be alive to qualify. Permitted concomitant medications were updated to include antiemetic. Clarification that Day 1 laboratory data did not need to be repeated if the Screening central safety laboratory data were collected on Day 1. |
||
25 Feb 2019 |
Amendment 2: Corrections in grammar made throughout document as necessary. Additional information regarding the total anticipated enrollment of subjects is contingent on sufficient number of evaluable subjects. Subjects with moderate renal insufficiency (CrCl >30 to <50 mL/min) will require TBPM-PI-HBr dosage adjustment to 300 mg q8h. Plasma PK Assessments: Updated to collect blood samples on Day 2 following an oral dose (first, second or third), instead of Day 1 / First Dose. Updated to collect blood samples on Day 2 following
an oral dose (first, second or third), instead of Day 1 / First Dose. Increased the number of PK samples collected from two (1 h and 6 h) to three (1, 4 and 8 h). Subjects with moderate renal insufficiency (CrCl >30 to <50 mL/min) will require TBPM-PI-HBr dosage adjustment to 300 mg q8h OR 1 dummy oral tablet q8h. Added that a decline in post-baseline renal function such that the estimated CrCl falls to <30 mL/min is possible reason for premature discontinuation from IP. Timing of Dose Administration. Subjects prematurely discontinued from IP for safety reasons and who require further antibacterial therapy for the cUTI/AP should be assessed as a clinical and microbiological failure at EOT and TOC. Definition of Clinical Cure was updated to specify that subjects must be alive to qualify. Subjects deemed clinical failures at
EOT or TOC should be considered for further diagnostic workup, including urinary tract imaging (e.g., ultrasound), to assess for undiagnosed anatomical, obstructive, or neurogenic abnormalities, according to the best clinical judgment of the Investigator was added. Definition of Microbiologic eradication was updated to specify that subjects must be alive to qualify. Definition of sustained microbiologic
eradication was updated to include requirements of no subsequent urine culture after TOC demonstrating recurrence of the original baseline
uropathogen. |
||
26 May 2020 |
Amendment 3: The intent of this criterion is to exclude HIV-positive subjects at risk for opportunistic infections (e.g., with AIDS or CD4 count <200 within the past year) Exclusion criteria updated accordingly to reflect this clarification. Specified that EOT ECG’s must be performed on day of last dose, not the following day as allowed for other EOT assessments. Clarification was added for Standard-of-care assessments performed at the site within the Screening period (within 24 hours of randomization) may be used to determine subject eligibility even if performed prior to signing the informed consent form (ICF). For example, the Schedule of Assessments Table notes that “urine cultures collected per standard-of-care up to 24 h prior to randomization may be used for eligibility”. Other routine clinical assessments may be used to determine eligibility if performed prior to informed consent but within the 24-hour Screening period, Screening Visit and Day 1 occur on the same day the focused physical exam on Day 1 are optional, clarification was added for SAE. The prolongation of hospitalization criterion is based on best clinical judgment of the Principal Investigator. For the purposes of this study, duration of intended hospitalization at the time of study randomization may be reasonably presumed to be approximately 14 days, as this is the maximum allowed duration of study drug. Therefore, cases of clinical failure leading to prolongation of hospitalization beyond approximately 14 days should be evaluated for the potential of meeting SAE criteria. The Medical Monitor should be contacted if help is needed in determining reportability of a potential SAE. Non-inferiority margin changed from -10% to -12.5%; added text summarizing rationale for change in non-inferiority margin. Added that aliquots should be collected “after the first dose of the study drug”. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |